Skip to main content
Smart Investors Daily
SL

NASDAQ · SLS

SELLAS Life Sciences Group, Inc.

Healthcare · Biotechnology

$14.86

Down-$3.09 (-17.21%)

Updated Nov 20, 2026, 2:38 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
211.34M
P/E ratio
-7.53
Dividend yield
0.00%
52-week range
$1.39 – $24.89
Volume
36.26M
Avg. volume
4.07M

Price performance · SLS

SLS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

SLS closed at $14.86 after 21 trading sessions, up 30.93% for the selected period.

Last close
$14.86
Period change
+30.93%
Period low
$7.47
Period high
$19.15
Daily close
View OHLC price history
SLS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$15.38$16.5399$14.23$14.8636.26M
Nov 18, 2026$19.51$21.40$17.22$17.9535.75M
Nov 17, 2026$24.105$24.89$16.70$19.15120.29M
Nov 16, 2026$7.74$8.39$7.235$7.477.97M
Nov 13, 2026$8.69$9.00$7.54$7.8611.17M
Nov 12, 2026$8.16$8.405$8.00$8.034.38M
Nov 11, 2026$8.59$8.59$8.08$8.423.89M
Nov 10, 2026$8.32$8.80$8.08$8.373.93M
Nov 9, 2026$8.165$8.87$7.8136$8.584.79M
Nov 6, 2026$8.03$8.42$7.14$8.427.62M
Nov 5, 2026$9.005$9.05$7.83$7.8810.74M
Nov 4, 2026$8.88$9.17$8.63$9.145.44M
Nov 3, 2026$8.72$9.18$8.57$8.875.05M
Nov 2, 2026$9.71$9.73$8.4801$8.5514.42M
Oct 30, 2026$9.63$9.79$9.30$9.686.26M
Oct 29, 2026$10.42$11.0949$9.85$10.1558.36M
Oct 28, 2026$12.20$12.44$9.705$10.3823.77M
Oct 27, 2026$11.33$12.29$11.25$12.176.22M
Oct 26, 2026$11.535$11.70$11.18$11.343.21M
Oct 23, 2026$11.29$11.59$11.08$11.543.28M
Oct 22, 2026$11.91$12.37$11.12$11.356.51M

Latest SLS news

The latest Smart Investors Daily articles mentioning SLS.

SLS research

Overview

Company profile and research snapshot.

Company profile

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.80
Implied upside
—
Analysts
—
SLS recent ratings
DateFirmRatingTarget
Jul 16, 2025Maxim GroupBuy—
Nov 22, 2023Cantor FitzgeraldOverweight—
Sep 7, 2023Cantor FitzgeraldOverweight—
Nov 15, 2022Alliance Global PartnersBuy—
Jun 28, 2022Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.